RBGLY vs UL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. RBGLY and UL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined RBGLY and UL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Reckitt Benckiser Group plc sells everyday health and cleaning products in close to every country. It now reports two businesses. Core Reckitt holds four categories: Self Care (Mucinex, Nurofen, Strepsils, Gaviscon), Germ Protection (Dettol and Lysol), Household Care (Finish dishwasher products, Vanish stain removers and Harpic toilet cleaners) and Intimate Wellness (Durex). Mead Johnson Nutrition, which sells Enfamil and Nutramigen infant formula, sits outside the core and is treated as non-core while the company considers all options for it. In 2025 group net revenue was ~£14.2 billion, and like-for-like growth excluding Essential Home was 5.0%. In the March 2026 quarter, Core Reckitt's ~£2.6 billion of net revenue split as ~£1.09 billion from emerging markets, ~£873 million from Europe and ~£638 million from North America, and Mead Johnson added ~£531 million.

Full RBGLY guide

Unilever PLC is one of the world's largest consumer-goods companies, and UL is its NYSE-listed ADR (the London line trades as ULVR, with a further listing in Amsterdam). After the late-2025 demerger of its ice cream arm, Unilever is organized around four business groups: Beauty & Wellbeing (Dove, Vaseline, and premium and wellness brands), Personal Care (deodorants, skin cleansing, and oral care such as Rexona and Lifebuoy), Home Care (laundry and cleaning brands like Persil and Cif), and Foods, also called Nutrition (Knorr, Hellmann's, and cooking products). A large share of turnover now comes from a concentrated set of roughly 30 Power Brands, which the company reports have been growing faster than the overall portfolio. Because it sells low-cost, repeat-purchase essentials, Unilever tends to hold up better than cyclical businesses in downturns, though it is exposed to input-cost inflation, currency swings, and slower volume growth in developed markets.

Full UL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• RBGLY drivers: Emerging markets as the growth engine; Fixing Europe and North America.
• UL drivers: Power Brands and premiumization; Growth Action Plan and cost discipline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Litigation is the risk that sets Reckitt apart from its peers. For UL, the main risk is that a slow-growth staples business trades on the credibility of its turnaround: if the Growth Action Plan does not lift volumes and margins as hoped, the stock can languish.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick RBGLY if you believe its drivers more; UL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the RBGLY and UL guides.

RBGLY. Reported revenue is falling because Essential Home left the group on December 31, 2025, which is why first-half 2026 net revenue (~£6.41 billion) came in below the prior year's ~£6.98 billion even as like-for-like sales grew 2.6%. Yahoo Finance shows RBGLY at ~11.5x trailing earnings, a figure flattered by disposal gains, and ~14x forward earnings, which is a lower multiple than many large consumer-staples peers. The forward yield of ~4.2% rests on a dividend that the company raised 5% for 2025 and again at the 2026 interim. The discount reflects slower growth in developed markets and the open-ended NEC litigation.

UL. Figures are qualitative and tied to the asOf date; verify live numbers before acting. Unilever is valued as a stable, cash-generative consumer staple rather than a fast grower, so its multiple hinges on whether the Growth Action Plan can lift volume growth and margins. Because it is an ADR of a euro-reporting company, currency moves affect the dollar figures US investors see, including the dividend, independent of how the underlying business performs.

Headline figures (approximate, October 2026): RBGLY shows net revenue (fy 2025, group) ~£14.2 billion, adjusted operating profit (fy 2025) ~£3.54 billion, 24.9% margin, net revenue (h1 2026) ~£6.41 billion, adjusted diluted eps (h1 2026) 152.1p, down 9.7%; UL shows business mix Four business groups after the ice cream demerger: Beauty & Wellbeing, Personal Care, Home Care, and Foods (Nutrition); verify live figures before acting, revenue scale Tens of billions of euros in annual turnover (reported in euros; UL is a dollar-denominated ADR), spread across roughly 190 countries; verify live figures before acting, underlying sales growth Mid-single-digit percentage in recent periods, led by Power Brands and beauty/personal care; verify the latest quarter before acting, dividend Pays a quarterly dividend and is widely held as a defensive income stock; treat any specific yield as a live figure to confirm before acting.

RBGLY and UL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined RBGLY and UL exposure against your real portfolio. It is not an investment adviser.